Barts Hospital

London, Greater London EC1M 6BQ

0 studies enrolling now · 5 studies all time

What they study most

Chemotherapeutic Toxicity, Clear-cell Metastatic Renal Cell Carcinoma, Colorectal Cancer Metastatic, Dyslipidemia, Myelosuppression-Adult, Symptomatic Neurogenic Orthostatic Hypotension, Type2 Diabetes, Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Studies at this site

• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): — Stopped early
• Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure — Completed
• Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) — Completed
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma — Completed